{"url_path":"/sec/pths/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1919246/0001919246-26-000070-index.html","accession_number":"0001919246-26-000070","cik":"0001919246","ticker":"PTHS","issuer_name":"Pelthos Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1919246/0001919246-26-000070-index.html","primary_entity_key":"0001919246","primary_entity_name":"Pelthos Therapeutics Inc."},"word_count":552,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nExhibit\nNumberDescription\n\n4.1\n[Form of Warrant issued pursuant to Venture Loan and Security Agreement dated as of January 12, 2026, by and among Pelthos Therapeutics Inc., LNHC, Inc., Channel Therapeutics Corporation and Horizon Technology Finance Corporation (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on January 13, 2026)](https://www.sec.gov/Archives/edgar/data/1919246/000175392626000097/g085079_ex4-1.htm)\n\n4.2\n[Form of Senior Debt Indenture (incorporated by reference to Exhibit 4.7 to the Registrant’s Registration Statement on Form S-3, filed with the SEC on February 2, 2026)](https://www.sec.gov/Archives/edgar/data/1919246/000175392626000231/g085075_ex4-7.htm)\n\n4.3\n[Form of Subordinated Debt Indenture (incorporated by reference to Exhibit 4.8 to the Registrant’s Registration Statement on Form S-3, filed with the SEC on February 2, 2026)](https://www.sec.gov/Archives/edgar/data/1919246/000175392626000231/g085075_ex4-8.htm)\n\n10.1\n[Asset Purchase Agreement, dated as of December 23, 2025, by and between Pelthos Therapeutics Inc., as Purchaser, and Hatchtech Pty Ltd ACN 098 559 409, as Seller (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on January 2, 2026)](https://www.sec.gov/Archives/edgar/data/1919246/000175392626000010/g085066_ex10-1.htm)\n\n10.2\n[Down Payment Agreement for Xeglyze Assets Purchase, dated as of November 20, 2025, by and between Hatchtech Pty Ltd, as Seller and Pelthos Therapeutics Inc. as Buyer (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed with the SEC on January 2, 2026)](https://www.sec.gov/Archives/edgar/data/1919246/000175392626000010/g085066_ex10-2.htm)\n\n10.3\n[Venture Loan and Security Agreement, dated as of January 12, 2026, by and among Pelthos Therapeutics Inc., LNHC, Inc., Channel Therapeutics Corporation and Horizon Technology Finance Corporation (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on January 13, 2026)](https://www.sec.gov/Archives/edgar/data/1919246/000175392626000097/g085079_ex10-1.htm)\n\n10.4\n[Employment Agreement between Pelthos Therapeutics Inc. and John M. Gay, dated April 10, 2026 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on April 10, 2026)](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000058/gayjohn_eax4x10x26xex101.htm)\n\n10.5*\n[First Amendment to Executive Employment Agreement between Pelthos Therapeutics Inc. and Scott Plesha, dated April 9, 2026](pths-20260331xexx105.htm)\n\n10.6*\n[First Amendment to Executive Employment Agreement between Pelthos Therapeutics Inc. and Sai Rangarao, dated April 6, 2026](pths-20260331xexx106.htm)\n\n31.1*\n[Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](pths-20260331xexx311.htm)\n\n31.2*\n[Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](pths-20260331xexx312.htm)\n\n32.1*\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](pths-20260331xexx321.htm)\n\n32.2*\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](pths-20260331xexx322.htm)\n\n101Interactive Data Files (embedded within the Inline XBRL document)\n\n104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)\n\n*Filed herewith.\n\n+Indicates management contract or compensatory plan.\n\nIn accordance with SEC Release 33-8238, Exhibits 31s and 32s are being furnished and not filed.\n\n75\n\nSIGNATURES\n\nPursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.\n\nPelthos Therapeutics Inc.\n\nDate: May 14, 2026\nBy:/s/ Scott Plesha\n\nName: Scott Plesha\n\nTitle: Chief Executive Officer and President (Principal Executive Officer)\n\nDate: May 14, 2026\nBy:/s/ John M. Gay\n\nName: John M. Gay\n\nTitle: Chief Financial Officer, Treasurer and Secretary\n(Principal Financial Officer, Principal Accounting Officer)\n\n76"}